Valsamo Anagnostou, MD, PhD

Dr. Anagnostou is an Associate Professor of Oncology, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Her long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies.

Education

• MD; National and Kapodistrian University of Athens School of Medicine (2005)
• PhD; National and Kapodistrian University of Athens School of Medicine (2011)
• Residency, Internal Medicine; Yale-New Haven Hospital (2013)
• Fellowship, Medical Oncology; Johns Hopkins University School of Medicine (2016)

Board Certifications

• American Board of Internal Medicine (General Internal Medicine) (2014)
• American Board of Internal Medicine (Medical Oncology) (2015)